Skip to main content
Premium Trial:

Request an Annual Quote

Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko

NEW YORK – Amoy Diagnostics, Riken Genesis, and Precision Medicine Asia (Premia) on Monday said that Japan's Ministry of Health, Labor, and Welfare has approved the AmoyDx PLC Panel as a companion diagnostic to identify non-small cell lung cancer patients eligible for Merck KGaA's tepotinib (Tepmetko).

Specifically, the MHLW has approved the AmoyDx PLC Panel — short for Pan Lung Cancer PCR Panel — for use in identifying patients with unresectable, advanced, or recurrent NSCLC whose tumors harbor MET exon 14 skipping alterations, making them eligible for treatment with tepotinib.

The MHLW approved tepotinib in March 2020, and the US Food and Drug Administration followed suit the next year. In August 2020, AmoyDx struck a companion diagnostic development deal with Merck KGaA to seek companion diagnostic approval for its PLC Panel alongside tepotinib in Japan. Riken Genesis and Premia have collaborated with AmoyDx on securing the approval.

The MHLW's companion diagnostic approval marks the fifth such approval for the AmoyDx PLC Panel, which is a PCR-based panel designed to evaluate 11 NSCLC driver genes. The test also has Japanese companion diagnostic approval for identifying NSCLC patients with EGFR, ALK, ROS1, and BRAF alterations, making them eligible for respective targeted therapies.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.